Spring Bank Discontinues the Development of Inarigivir to Treat Patients with Chronic Hepatitis B Virus

 Spring Bank Discontinues the Development of Inarigivir to Treat Patients with Chronic Hepatitis B Virus

Spring Bank Discontinues the Development of Inarigivir to Treat Patients with Chronic Hepatitis B Virus

Shots:

  • Spring Bank has discontinued the development of Inarigivir soproxil due to the occurrence of one patient death in its P-IIb CATALYST study
  • The discontinuation allows Spring Bank to focus on immuno-oncology & inflammation including its SB 11285 IV STING agonist clinical program in oncology, STING antagonist for inflammatory diseases, and its STING agonist ADC program
  • SB 11285 is a STING agonist, currently being evaluated in P-Ia/Ib study with the expected initiation of IND enabling activities for its orally available STING antagonist and advancement in STING agonist ADCs’ pipeline

Click here ­to­ read full press release/ article | Ref: Spring Bank  | Image:  Spring Bank

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post